Two recent studies indicate that STING agonism could also attenuate AML growth and survival through nonautonomous cellular mechanisms (16, 42), suggesting that targeting STING in AML may have multiple antileukemia effects by simultaneously targeting leukemia cells as well as their tumor-supportive microenvironment. The gene discussed is STING1; the disease is leukemia.